Press Releases

Press Releases

Media Contact:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com

Date Title and Summary Additional Format
October 14, 2020 Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
Completed recent IPO raising approximately $238 .5 million in gross proceeds On track for multiple IND filings SAN FRANCISCO , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics Inc.  (Nasdaq: NRIX), a biotechnology company developing targeted protein modulation drugs, today reported financial
October 6, 2020 Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
SAN FRANCISCO , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. , (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3 rd Targeted Protein Degradation (TPD) Summit held virtually.
July 23, 2020 Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering
SAN FRANCISCO , July 23, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nurix ), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share.
July 13, 2020 Nurix Therapeutics Announces Addition of Dr. Jason Kantor to its Management Team
SAN FRANCISCO, July 13, 2020 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Jason Kantor as senior vice president, finance and investment strategy. In this role, Dr. Kantor will be responsible for communicating the vision
June 25, 2020 Nurix Therapeutics Announces Formation of DeCART Therapeutics to Advance New CAR T Therapies Using Targeted Protein Modulation
SAN FRANCISCO, June 25, 2020 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.
March 12, 2020 Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline
SAN FRANCISCO, March 12, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced it has closed an oversubscribed $120 million financing. The round was led by Foresite Capital with participation from Bain Capital Life Sciences, Boxer Capital
February 27, 2020 Nurix Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
SAN FRANCISCO, February 27, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced that CEO Arthur Sands will present at the Cowen & Co. 40th Annual Health Care Conference on Wednesday, March 4, 2020, 3:30 PM ET in Boston, MA.
January 9, 2020 Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies
SAN FRANCISCO, Jan. 09, 2020 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc., a company researching novel therapies that control degradation of disease-causing proteins, today announced a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted
January 8, 2020 Nurix Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, January 8, 2019 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs announced today that CEO Arthur Sands will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 8:30 a.m. PST in San Francisco.